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Abstract 
Background In non-valvular atrial fibrillation (AF), oral anticoagulation reduces the risk of 
thromboembolism such as stroke and systemic embolism (SSE), but increases the risk of 
major bleeding such as intracranial haemorrhage (ICH). The risk-benefit balance between 
SSE versus ICH can be expressed as the net clinical benefit (NCB); however, the risk of SSE 
and ICH varies according to clinical factors that can be assessed using CHADS2, CHA2DS2-
VASc (both quantifying risk of stroke) and HAS-BLED (quantifying risk of major bleeding) 
scores, respectively.  
Methods  Using established modelling based on event rates for thromboembolism and 
haemorrhage in the Danish nationwide cohort study, we tested the hypothesis that 
edoxaban has a superior NCB compared with warfarin.  
Results  In our overall model, compared to no treatment, warfarin had a NCB of 0.26 
(95% CI 0.24,0.28) events prevented per 100 patient years, edoxaban 60 mg daily a NCB of 
0.71 [0.69,0.76], and edoxaban 30 mg daily a NCB of 0.71 [0.0.68,0.73]. When compared to 
no treatment, both doses of edoxaban have superior NCB values than those of warfarin at all 
CHADS2 and CHA2DS2-VASc scores. At CHADS2 ≥2 and CHA2DS2-VASc ≥2, edoxaban 60 mg 
dose had a better NCB than the 30 mg dose or warfarin, when compared to no treatment.    
With HAS-BLED score ≥3, both doses of edoxaban had a positive NCB compared to warfarin, 
at CHADS2 or CHA2DS2-VASc ≥2. 
Conclusion   Our modelling study suggests that both 30 mg and 60 mg doses of edoxaban 
have a favourable NCB compared to warfarin, and the degree of benefit differs according to 
CHADS2, CHA2DS2-VASc and HAS-BLED scores.  At CHA2DS2-VASc score ≥2, both edoxaban 
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doses were superior to warfarin, but compared to no treatment, the 60 mg dose had a 
better NCB than the 30mg dose or warfarin.  
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
4 
 
Introduction 
As non-valvular atrial fibrillation (AF) confers an increased risk of stroke and systemic 
embolism, guidelines recommend oral anticoagulation (OAC) to reduce this risk1. However, 
OAC also brings an increased risk of major bleeding, such as gastrointestinal and intracranial 
haemorrhage (ICH). The concept of net clinical benefit (NCB) has been used to quantify the 
balance between a reduced risk of stroke and systemic embolism compared to an increased 
risk of ICH with OAC in the setting of stroke prevention in patients with AF. Indeed, patients 
at highest risk of stroke and systemic embolism gain the greatest benefit from OAC2.  
 
The risk of stroke and systemic embolism in AF is not homogeneous, but depends upon the 
presence of certain clinical factors, alone or in combination. Major stroke risk factors have 
been combined to give the CHADS2 (Chronic heart failure, Hypertension, Age >75 years, 
Diabetes mellitus (all 1 point), Stroke or transient ischaemic attack (2 points)) and CHA2DS2-
VASc (Chronic heart failure, Hypertension, Age >75 years (2 points), Diabetes mellitus, 
Stroke, systemic embolism or transient ischaemic attack (2 points), Vascular disease, Age 65-
74, Sex category i.e. female) scores3,4.  Both scores are used to assess the risk of stroke and 
systemic embolism in AF, and incorporated to guidelines for risk stratification1.   The use of 
OAC is also associated with bleeding (including ICH), and once more, certain risk factors 
have been used to develop the HAS-BLED (Hypertension, Abnormal liver/renal function, 
prior Stroke/thromboembolism, Bleeding tendency, Labile international normalised ratio, 
Elderly (e.g. age over 65 years), Drugs (e.g. concomitant use of aspirin or NSAIDs, or alcohol 
excess) score for bleeding risk stratification6.    
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The vitamin K antagonists (VKAs, e.g. warfarin) have traditionally been the only available 
OAC. More recently, several non-VKA oral anticoagulants (NOACs) have shown favourable 
efficacy and safety results, compared with warfarin7-10. Of these NOACs, the oral factor Xa 
inhibitor edoxaban, at low and high doses of 30 mg or 60 mg (respectively) once daily, was 
found to be non-inferior to warfarin in protecting against stroke and systemic embolism in 
AF, and was associated with significantly less ICH, major bleeding and death from 
cardiovascular causes than warfarin10.  
 
Highly structured randomised controlled trials of NOACs may fail to translate to a ‘real 
world’ population, where the value of these agents also needs to be determined and 
compared with that of a VKA. In data from the Danish National Patient Registry on patients 
with AF diagnosed between 1997 and 200811, we demonstrated that dabigatran, 
rivaroxaban and apixaban would each be likely to have a favourable NCB (i.e. fewer cases of 
stroke and systemic embolism and fewer cases of ICH) compared to warfarin12. It is unclear 
whether or not edoxaban offers the same advantages, as each of the NOACs has different 
characteristics, and so any such data would be a potentially valuable addition to our 
management of these drugs. Using the same modelling approach, we hypothesised a 
superior ‘real world’ NCB for edoxaban with respect to warfarin, and that this benefit would 
vary according to the risk of stroke or systemic embolism and ICH (as defined by CHADS2, 
CHA2DS2-VASc and HAS-BLED scores, respectively) on the basis of clinical trial outcome 
data10.   
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Methods 
Study population 
The cohort used in this model was patients with non-valvular AF from the Danish National 
Patient Registry11 who were diagnosed with AF between 1997 and 2008. AF was defined by a 
discharge diagnosis of AF or atrial flutter, absence of previous diagnosis of mitral or aortic 
valve disease, and absence of mitral or aortic valve surgery. The Danish National Patient 
Registry has registered all hospital admissions since 1978. At discharge each admission is 
coded by one primary and, if necessary one or more secondary diagnoses according to the 
International Classification of Diseases. The diagnosis of AF has been well-validated from 
Danish registries and the Patient Registry is linked to the Danish Registry of Medicinal 
Product Statistics (prescription registry), the National Causes of Death Registry, and the civil 
registration system providing a permanent and unique person registration number for all 
Danish citizens. Detailed history, including pharmacotherapy, and risk stratification scores 
for stroke and systemic embolism and major bleeding (i.e., CHADS2, CHA2DS2-VASc
 and HAS-
BLED) were available for all patients3,4,6. Published data of 96,308 patients (58,883 not 
treated with either an anti-platelet or with warfarin, and 37,425 patients treated with 
warfarin)  followed up for up to 12 years with a mean of 3.83 years (= 368,860 person years) 
also included outcomes, including rates of ischaemic stroke, ICH, thromboembolism, 
cardiovascular death and acute coronary syndromes11. Treatment periods were determined 
for each patient by dividing the number of tables dispensed with the estimated daily 
dosage, a method described in detail previously and which allows the patient to be 
considered as at risk only during treatment periods13-15. These data were compared with 
those from the ENGAGE AF-TIMI 48 trial of edoxaban10. 
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Model assumptions 
The event rates per 100 person-years for ischaemic stroke and systemic embolism and 
major bleeding  (ICH, gastrointestinal bleeding, bleeding from the urinary tract, etc.) were 
calculated using data from the Danish nationwide cohort study population for patients on 
no treatment with and on warfarin, stratified by stroke risk as predicted by their CHADS2 
and CHA2DS2VASc scores
11. Using the modified intention to treat primary end points of 
stroke and systemic embolic event data (table 2), and the ICH data (table 3) of the ENGAGE 
AF study10, the equivalent event rates were estimated for the Danish population.  For this 
model, the ’real world’ hazard ratios of the sum of stroke and systemic embolic event with 
edoxaban compared to warfarin were taken to be 0.79 for edoxaban 60 mg od and 1.07 for 
edoxaban 30 mg od. The ’real world’ hazard ratios of ICH with edoxaban compared to 
warfarin were assumed to be 0.47 for edoxaban 60 mg od and 0.26 for edoxaban 30 mg 
od10. The relative risks of stroke, systemic embolic event and ICH were assumed to be 
constant across all categories of thrombosis risk and bleeding risk.  
 
The number of patients needed to treat (NNT) to prevent one ischaemic stroke and systemic 
embolism per year was calculated as the reciprocal of the absolute risk reduction (i.e. 
1/ARR), that is, the event rate on no treatment minus the event rate on treatment12. NNTs 
were also calculated for ICH with a negative value denoting the ‘number needed to harm’ 
(NNH)12, that is, the number of patients treated in order to cause one ICH. The NCB of each 
anticoagulant compared with no treatment was calculated using the formula: (stroke and 
systemic embolism rate on no treatment minus stroke and systemic embolism rate on 
anticoagulant) - 1.5 (ICH rate on anticoagulant minus ICH rate on no treatment)2. The 
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weighting of 1.5 reflects the relative impact, in terms of death and disability, of an ICH. NNTs 
and NNHs are adjusted for a one-year period.  
 
Results 
Table 1 shows the event rates for stroke and systemic embolism per 100 patient years, and 
classified according to risk. In order to estimate the rates of stroke and systemic embolism 
whilst taking edoxaban, we multiplied the hazard ratios from the ENGAGE trial10 with the 
rates from the Danish cohort12.  The overall rate of stroke and systemic embolism whilst on 
warfarin was 0.53 [0.51,0.56] events/100 patient years12, whilst on edoxaban 60 mg once 
daily the rate of 0.42 [0.40,0.44]) was well under half that of no treatment (1.0 [0.96,1.05]12 
events/100 patient-years). These data translate to NNT of 212 patients with AF for warfarin 
and 172 for edoxaban 60 mg. The event rate for edoxaban 30 mg daily (0.57 [0.55,0.60] 
events/100 patient-years) and NNT of 232 patients was equivalent to that of warfarin, but 
was higher than that of edoxaban 60 mg.   For both anticoagulants the event rates were 
greater with increasing CHADS2 and CHA2DS2-VASc scores. NNTs for those on edoxaban and 
warfarin were lower with increasing scores.   
 
Table 2 shows the event rates for ICH per 100 patient years, and when classified according 
to risk of thromboembolism. The overall rate of ICH whilst on warfarin (0.44 [0.42,0.45] 
events/100 patient-years) was worse than for no treatment (0.30 [0.29,0.31] events/100 
patient-years)12. These data translate to warfarin causing one ICH per 714 patients treated 
in a year (i.e. a NNH of -714).  In order to estimate the rates of ICH whilst taking edoxaban, 
we multiplied the hazard ratios for ICH from the ENGAGE trial10 with the rates of ICH from 
the Danish cohort12.  In this model, both doses of edoxaban had significantly lower adjusted 
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rates of ICH than that of warfarin and no treatment (edoxaban 30 mg 0.11 [0.11,0.12] 
events/100 patient-years, NNT 526; edoxaban 60 mg 0.21 [0.20,0.21] events/100 patient-
years, NNT 1,111) and the rate of ICH of 30 mg dose of edoxaban was superior to that of the 
60 mg dose. As with stroke and systemic embolism, for both anticoagulants, the event rates 
were greater with increasing CHADS2 and CHA2DS2-VASc scores whilst the NNTs fell with 
increasing scores, except for warfarin and CHADS2 score.  
 
NCB of warfarin and edoxaban when compared with no treatment  
Table 3 presents the NCB of warfarin and edoxaban when compared with no treatment. 
Warfarin use is associated with a reduced rate of stoke and systemic embolism (Table 1) but 
an increased rate of ICH (Table 2) compared with no treatment. For any AF patient requiring 
OAC, the NCB is 0.26 [0.24,0.28] events prevented/100 patient-years if treated with 
warfarin. Similarly, the NCB for edoxaban 30 mg is 0.71 [0.68,0.73] events prevented, and for 
edoxaban 60 mg, 0.71 [0.69,0.76] events prevented.   
In considering risk profiles with the CHADS2 and CHA2DS2-VASc scores, differences emerge. 
At all CHADS2 scores, and CHA2DS2-VASc score 2-9, warfarin has a positive NCB compared to 
no treatment, but at CHA2DS2-VASc scores 0 and 1, warfarin has no positive benefit over no 
treatment. At all CHADS2 and CHA2DS2-VASc scores, both doses of edoxaban have superior 
NCB values than no treatment. At CHADS2 scores 0 and 1, the two edoxaban doses bring 
similar NCBs compared to each other, and are superior to no treatment [Table 3], but at 
CHADS2 2-6, the 60 mg dose had a better NCB than the 30mg dose or warfarin.   At CHA2DS2-
VASc scores 0 and 1, both doses of edoxaban had marginally positive NCBs compared to no 
treatment, but the 30mg dose had superior NCBs than the 60 mg dose. At CHA2DS2-VASc 
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score 2-9, the 60 mg dose had a better NCB than the 30 mg dose or warfarin.  For both 
OACs, NCBs increased with increasing CHADS2 and CHA2DS2-VASc scores. 
 
NCB for edoxaban 30 mg and 60 mg compared with warfarin  
Table 4 shows the NCB for edoxaban 30 mg and 60 mg compared with warfarin, according to 
CHADS2, CHA2DS2-VASc and HAS-BLED scores. At low bleeding risk (HAS-BLED score <2), both 
edoxaban doses had superior NCB to warfarin regardless of CHADS2 or CHA2DS2-VASc score.  
At a high risk of bleeding (HAS-BLED score ≥3), and at CHADS2 0 and CHA2DS2-VASc score 1, 
neither dose of edoxaban had superior NCB to warfarin and the two edoxaban doses had 
similar NCBs. At all other CHADS2 and CHA2DS2-VASc scores, both doses of edoxaban had 
superior NCBs than warfarin, and was similar for the two edoxaban doses. These results are 
illustrated in figure 1. 
 
Sensitivity analysis 
We performed a further analysis based on the likelihood that the rate of ICH were twice that 
observed in the trial, and that the rate of stroke and systemic embolism were lowered by 
50%.  Results presented in supplementary table 1 indicate that outcome would not be the 
same, with in some cases the NCB of warfarin would become not significant, whereas all 
cases of the use of edoxaban would still be significant, except that for patients with 
CHA2DS2VASc 1, edoxaban 30mg od would provide no clear NCB advantage. This translates, 
in supplementary table 2, to no changes in the extent to which either doses of edoxaban are 
or are not preferable to warfarin.    
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Discussion 
In this modelling analysis, we have shown that the NCBs and NNTs of the 30 mg and 60 mg 
doses of edoxaban, with respect to warfarin, are favourable but differ according to CHADS2, 
CHA2DS2-VASc and HAS-BLED scores.  At high stroke risk (i.e. CHA2DS2-VASc score ≥2), both 
edoxaban doses were superior to warfarin, but compared to no treatment, the 60 mg dose 
had a better NCB than the 30mg dose or warfarin.  With high bleeding risk (HAS-BLED ≥3), 
both doses of edoxaban had a positive NCB compared to warfarin, at CHADS2 or CHA2DS2-
VASc scores ≥2. 
 
When using an OAC in AF patients, the benefit of a reduction in the risk of a thrombotic 
event such as stroke and systemic embolisation must be weighed against the risk of major 
bleeding such as ICH. However, the risk of stroke and thromboembolism in an individual 
varies markedly according to the sum of certain risk factors. As we previously reported11,12, 
the NCB is only negative with warfarin at a CHA2DS2-VASc score 0 or 1, reflecting the ‘truly 
low risk’ status of these patients. In our model for the present study, without risk factor 
stratification, both doses of edoxaban are predicted to result in lower rates of both types of 
events (thrombotic and haemorrhagic, and so equivalent NCBs) compared with warfarin.  
Our prediction that a NOAC brings a reduction of over 50% in the risk of ICH in a real world 
database is entirely in line with a recent meta-analysis16. However, these data assume each 
risk regardless of concurrent clinical and demographic features. 
 
Classifying stroke risk by the CHADS2 method, at low and moderate risk of stroke, both 
doses of edoxaban provide similar improved NCB over warfarin. At the high risk of stroke, 
high-dose (60 mg) edoxaban is superior to both low dose (30 mg) edoxaban and warfarin. 
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The CHA2DS2-VASc system recognises a limitation inherent in CHADS2, in that the latter 
places more patients at low risk of stroke than the former, potentially denying treatment to 
some4. This is borne out by data indicating that at low CHA2DS2-VASc scores of 0 and 1, 
when compared to no treatment, warfarin causes more harm than good whereas at a 
CHADS2 score of 0, the use of warfarin can be justified in some patients. At a low and 
moderate CHA2DS2-VASc risk of stroke (scores 0 and 1), edoxaban 30 mg provides more 
benefit than edoxaban 60 mg, whereas at high risk (CHA2DS2-VASc score 2-9), edoxaban 60 
mg is preferred.   
 
Practitioners and patients alike fear haemorrhage, the risk of which can be determined by 
the HAS-BLED score5. When risk of bleeding is low (HAS-BLED score <2), our modelling data 
predict that edoxaban 30 mg is the preferred dose regardless of stroke risk, except when 
defined by CHADS2 2-6, where the two doses bring equivalent benefit. Patients with a high 
HAS-BLED score (≥3), and a low risk of stroke according to CHADS2 (score 1) or a moderate 
risk of stroke according CHA2DS2-VASc (score 1) will benefit equally from any oral 
anticoagulant. Due to low numbers of patients and events, our analyses of CHA2DS2VASc 
score 0 and high bleeding risk may be unreliable. Patients at high risk of stroke according to 
CHADS2 score 2-6 or CHA2DS2VASc score 2-9 gain the same benefit from either dose of 
edoxaban. The NCB data are broadly comparable with those of other NOACs, which have 
NCBs between 0.58 and 3.76 events prevented/100 patient-years12.  
Limitations 
We note several limitations of this analysis. Our model calls for merging of data from a 
formal clinical trial10 with that from a community population11, two groups who may differ 
in clinical profiles. Indeed, we assume the relative risk observed in a RCT would be similar to 
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the one happening in the real-world population, which may be an oversimplification; 
indeed, patients in RCTs are generally not representative of the general population and 
therefore, the risks that are observed in RCTs cannot be assumed to be the same in the ‘real 
world’ population. In addition, other models have been used, so results may be different. 
Accordingly, there may be error in the estimates of the effects of edoxaban compared to 
warfarin. The mean (standard deviation) CHADS2 score in the ENGAGE AF-TIMI 48 trial was 
2.8 (1.0)10, that for the Danish cohort11 is estimated to be perhaps 1.25 (0.8), indicating that 
the latter are at considerably less risk of stroke. Furthermore, we cannot determine the 
degree of warfarin anticoagulation control in the two groups and assume they are equal: it 
is possible that INR control is less rigorous in the community and this may impact on 
outcomes 17,18. Furthermore, since warfarin doses vary frequently, we acknowledge the 
limitation that this is difficult to extrapolate daily dosage and thus drug coverage based on 
administrative data. The equation of Singer et al2 balances risk of ischaemic stroke and 
systemic emboli with those of any ICH, and did not include a sudden neurological deficit 
lasting less than 24 hours (i.e. a transient ischaemic attack (TIA). Olesen et al11 defined 
thromboembolism as peripheral artery embolism, TIA and ischaemic stroke, and bleeding as 
gastrointestinal, urinary tract and airways as well as intracranial. These differences may also 
lead to error. Statistical differences at p<0.05 are assumed if 95% confidence intervals fail to 
overlap, but these intervals are defined by power in terms of number of events and number 
of patients (in the Danish cohort11, 38,546 patients had a HAS-BLED score >3, whereas 
93,826 (2.4x more) had a HAS-BLED score <2). This may explain why, at a CHADS2 score of 0, 
a 56% better NCB for edoxaban 30 mg at HAS-BLED score >3 compared to edoxaban 60 mg 
is not significant (table 4), whereas a smaller 31% at CHADS2 score of 1 and 26% at 
CHA2DS2VASc score of 2-9 of the respective better NCB for the 30 mg dose at HAS-BLED 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
14 
 
score >2 is statistically significant. Accordingly, we note the caveat that wide (and so 
overlapping) confident intervals consequent to low power may give rise to false negatives. 
Finally, we note that Danish cohort was studied between 1997 and 2008, whilst the 
ENGAGE-AF trial was conducted between 2008 and 2010. Accordingly, differences in general 
clinical practice and different drugs and other treatments over more than a decade may also 
lead to error or residual confounding.  A further limitation is that the results from the 
Engage AF-TIMI 48 trial of edoxaban10 may not reflect the real world, and that one might 
expect that the risk of ICH would be greater. In addressing this point our sensitivity analysis 
based on the likelihood that the rate of ICH were twice that observed in the trial, and that 
the rate of stroke and systemic embolism were lowered by 50% translated, to no profound 
changes in the extent to which either doses of edoxaban are or are not preferable to 
warfarin.    
 
In conclusion, based on this modelling analysis of NCB, edoxaban is preferable over warfarin 
for ‘all comers’ with AF, with the two edoxaban doses apparently bringing the same 
favourable NCB compared to warfarin. However, degree of benefit differs according to 
CHADS2, CHA2DS2-VASc and HAS-BLED scores. At CHA2DS2-VASc score ≥2, both edoxaban 
doses were superior to warfarin, but compared to no treatment, the 60 mg dose had a 
better NCB than the 30mg dose or warfarin.  Assessment of the patient’s risk profile may 
allow a more tailored and efficient approach to stroke prevention. 
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Table 1: Event rates (95% confidence interval) modelled for stroke and systemic embolism 
per 100 patient years in a real world cohort adjusted for effect size for no treatment, 
warfarin, or 30 mg or 60 mg dose of edoxaban. 
 
 No 
Treatment 
Warfarin 
(dose 
adjusted) 
NNT Edoxaban 
(30 mg) 
 
NNT Edoxaban  
(60 mg) 
 
NNT 
All  
subjects 
1.00 
(0.96,1.05) 
0.53 
(0.51,0.56) 
212 0.57 
(0.55,0.60) 
232 0.42  
(0.40,0.44) 
172 
        
CHADS2 score        
0 0.20 
(0.18,0.22) 
0.10 
(0.09,0.11) 
1000 0.11 
(0.10,0.12) 
1111 0.08  
(0.07,0.09) 
833 
1 1.00 
(0.92,1.09) 
0.50 
(0.46,0.55) 
200 0.53 
(0.49,0.59) 
213 0.39  
(0.36,0.43) 
164 
2-6 3.01 
(2.85,3.16) 
1.65 
(1.56,1.74) 
74 1.76 
(1.67,1.86) 
80 1.30  
(1.23,1.38) 
58 
CHA2DS2-VASc 
score 
       
0 0.07 
(0.06,0.09) 
0.04 
(0.03,0.05) 
3333 0.04 
(0.03,0.05) 
3703 0.03  
(0.02,0.05) 
2500 
1 0.10 
(0.09,0.12) 
0.05 
(0.04,0.06) 
2000 0.05 
(0.04,0.06) 
2128 0.04  
(0.03,0.05) 
1667 
2-9 2.00 
(1.91,2.10) 
1.08 
(1.02,1.12) 
109 1.16  
(1.09,1.22) 
119 0.85  
(0.81,0.88) 
87 
 
 
NNT (number needed to treat): number of patients needed to treat to prevent one ischaemic 
stroke or systemic embolism per year. NNT is calculated as 1/ARR, where ARR is the absolute risk 
reduction, i.e. event rate on no treatment-event rate on treatment.  
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Table 2: Event rates (95% confidence interval) modelled for intra-cranial haemorrhage per 
100 patient years in a ‘real world cohort’ taking 30 mg or 60 mg dose of edoxaban 
adjusted for effect size for no treatment and warfarin. 
 
 No 
Treatment* 
Warfarin 
(dose 
adjusted)* 
NNH Edoxaban 
(30 mg) 
 
NNT Edoxaban 
(60 mg) 
 
NNT 
All subjects 0.30 
(0.29,0.31) 
0.44 
(0.42,0.45) 
714 0.11 
(0.11,0.12) 
 
526 0.21 
(0.20,0.21) 
 
1,111 
CHADS2 score        
0 0.10 
(0.09,0.11) 
0.15 
(0.14,0.17) 
2000 0.04 
(0.04,0.04) 
1667 0.07 
(0.07,0.08) 
3,333 
1 0.30 
(0.28,0.32) 
0.39 
(0.37,0.42) 
1111 0.10 
(0.10,0.11) 
500 0.18 
(0.17,0.20) 
833 
2-6 0.40 
(0.38,0.42) 
0.44 
(0.41,0.46) 
2500 0.11 
(0.11,0.12) 
345 0.21 
(0.19,0.22) 
526 
CHA2DS2-VASc 
score 
       
0 0.05 
(0.04,0.06) 
0.09 
(0.08,0.11) 
2500  0.02 
(0.02,0.03) 
3,333 0.04 
(0.04,0.05) 
10,000 
1 0.10 
(0.09,0.11) 
0.14 
(0.13,0.16) 
2500 0.04 
(0.03,0.04) 
1,667 0.07 
(0.06,0.08) 
3,333 
2-9 0.30 
(0.29,0.31) 
0.36 
(0.34,0.37) 
1667 0.09 
(0.09,0.10) 
476 0.17 
(0.16,0.17) 
769 
 
NNT: number of patients needed to treat to prevent one ICH per year. NNH = number 
needed to harm, i.e. the number of patients needed to treat to cause an ICH. NNT and NNH 
are calculated as 1/ARR, where ARR is the absolute risk reduction, i.e. event rate on no 
treatment-event rate on treatment. *Data from reference 11.  
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Table 3: Net clinical benefit (95% confidence interval) of warfarin and 30 mg and 60 mg 
doses of edoxaban compared to no treatment.  
 
 
 
 
Warfarin 
(dose  
adjusted) 
Edoxaban 
(30 mg) 
Edoxaban 
(60 mg) 
    
All  
subjects 
0.26 
(0.24,0.28) 
0.71 
(0.68,0.73) 
0.71 
(0.69,0.76) 
    
CHADS2 score    
0 0.02 
(0.01,0.03) 
0.18 
(0.15,0.20) 
0.16 
(0.14,0.17) 
1 0.36 
(0.32,0.39) 
0.77  
(0.70,0.81) 
0.79 
(0.72,0.84) 
2-6 1.3 
(1.2,1.4) 
1.68  
(1.58,1.75) 
1.99 
(1.90,2.08) 
    
CHA2DS2-VASc 
score 
   
0 -0.03 
(-0.03, -0.035) 
0.07  
(0.06,0.08) 
0.05 
(0.04,0.05) 
1 -0.01 
(-0.01, -0.015) 
0.14  
(0.14,0.16) 
0.10 
(0.10,0.11) 
2-9 0.83 
(0.81,0.89) 
1.15  
(1.12,1.19) 
1.34  
(1.29,1.43) 
 
Net clinical benefit (NCB)[Events prevented per 100 person-years (95% confidence interval)] 
is calculated as annualised (stroke and systemic embolism rate off treatment – stroke and 
systemic embolism rate on treatment) - 1.5 x (ICH rate on treatment – ICH rate off treatment)
2.  
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Table 4: Net clinical benefit (95% confidence interval) of 30 mg and 60 mg doses of 
edoxaban versus warfarin on the risk of stroke, systemic embolism and ICH risk as 
assessed by the CHADS2, CHA2DS2-VASc and HAS-BLED scores. 
 
  
HAS-BLED Score ≤2 
 
HAS-BLED Score ≥3 
 
Edoxaban  
(30 mg) 
 
 
Edoxaban 
(60 mg) 
 
Edoxaban  
(30 mg) 
 
 
Edoxaban  
(60 mg) 
CHADS2 
0 1.80  
(1.59,2.05) 
1.16 
(1.01,1.34) 
1.20 
(-0.74,3.36) 
0.77 
(-0.99,2.64) 
1 2.34 
(2.10,2.61) 
1.78  
(1.58,2.01) 
1.96 
(1.34,2.60) 
1.44 
(0.91,1.98) 
2-6 3.29 
(2.94,3.64) 
2.77  
(2.46,3.09) 
3.84 
(3.40,4.30) 
3.36 
(2.96,3.78) 
CHA2DS2-VASc 
0 2.06 
(1.65,2.49) 
1.30 
(1.00,1.58) 
- - 
1 1.65  
(1.34,1.97) 
1.05 
(0.81,1.29) 
1.21 
(-0.25,2.89) 
0.82 
(-0.48,2.19) 
2-9 2.63 
(2.42,2.84) 
2.09 
(1.91,2.26) 
3.43 
(3.07,3.80) 
2.94 
(2.61,3.28) 
 
Net clinical benefit (NCB) = events prevented per 100 patient-years (95% confidence 
interval) of edoxaban is calculated as annualised NCB on warfarin12 - [1-relative risk of 
stroke and systemic embolism for edoxaban10 x stroke and systemic embolism rate on 
warfarin11]+[1.5x (1-relative risk for ICH on edoxaban10 x rate of ICH on warfarin11)], 
modified from Singer et al2 .  
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Fig. 1 
